Jim Cramer: Stop Speculating on Deals
I'm all in favor of mergers and acquisitions -- the more we get, the higher the stock market goes -- but I am not in favor of making conclusions based on tips about deals.
Why a Walgreens Buyout Could Stink for Corporate Bond Investors
Reports of two potentially major buyouts show the risks of late-cycle corporate bond investing.
That's It for Fitbit As I Take the Money and Run
Let others wait and see if someone comes in with a better offer than Alphabet's bid for Fitbit; this value investor is taking his profit and leaving the table.
3 Stocks to Consider Amid Possible Consolidation in Luxury Retail
The buyout offer for Tiffany & Co. from Louis Vuitton's parent could spark more deals; this trio of sagging stocks could make for targets.
Fitbit Shares Shape Up on Reports of Offer From Alphabet
The maker of wearable fitness devices has seen its stock sprint higher on the buyout news after languishing this summer near multi-year lows.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Big Biotech Receives Some Needed Shots in the Arm
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
Raytheon Could Rally to the $230 Area in the Months Ahead - How to Buy It Now
Let's review the charts and indicators to see what they are showing today.
Possible M&A Surrounds These 3 Stocks
M&A activity has generally slowed.
The Cannabis Sector and Its Dot-Com Like Meltdown
Black-market vaping has made the entire cannabis group toxic.